INDUCTION OF SUSTAINED PATENCY AFTER CLOT-SELECTIVE CORONARY THROMBOLYSIS WITH HYBRID-B, A GENETICALLY ENGINEERED PLASMINOGEN-ACTIVATOR WITH A PROLONGED BIOLOGICAL HALF-LIFE

被引:13
作者
WEINHEIMER, CJ
JAMES, HL
KALYAN, NK
WILHELM, J
LEE, SG
HUNG, PP
SOBEL, BE
BERGMANN, SR
机构
[1] WASHINGTON UNIV,SCH MED,DIV CARDIOVASC,BOX 8086,660 S EUCLID AVE,ST LOUIS,MO 63110
[2] WYETH LABS,RADNOR,PA 19087
关键词
FIBRINOLYSIS; T-PA; CORONARY THROMBOSIS;
D O I
10.1161/01.CIR.83.4.1429
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Despite the utility of tissue-type plasminogen activator (t-PA) in eliciting coronary thrombolysis clinically, early reocclusion remains a problem, occurring despite anticoagulation in 5-30% of patients with initially successful recanalization. This study evaluated the utility of Hybrid-B, a molecular variant of t-PA with a prolonged half-life in the circulation, in eliciting coronary thrombolysis and maintaining patency in the presence of a continuing thrombogenic stimulus. Methods and Results. In intact, anesthetized dogs, either 18 mg Hybrid-B over 30 minutes (n = 15) or 50 mg t-PA (Activase) over 60 minutes (n = 8) was administered starting 60 minutes after left anterior descending coronary artery occlusion was induced with a thrombogenic copper coil. Time to lysis averaged 54 +/- 26 (means +/- SD) minutes and 64 +/- 34 minutes with Hybrid-B and t-PA, respectively (p = NS). When Hybrid-B was administered as a bolus (20 mg over 1 minute) to induce a high initial concentration in blood, time to lysis was shortened markedly and averaged 15 +/- 5 minutes. Dogs given Hybrid-B by either infusion or bolus exhibited prolonged time to reocclusion (337 +/- 192 minutes compared with 192 +/- 125 minutes in dogs given t-PA, p < 0.03), reflecting maintenance of a subthrombolytic but persistently active concentration of activator in blood. Despite the persistence of Hybrid-B in blood, concentrations of fibrinogen and alpha-2-antiplasmin were not depleted markedly and remained at 77 +/- 25 and 56 +/- 24%, respectively, of control values. Conclusions. Thus, Hybrid-B, a novel variant of t-PA with unique pharmacokinetic properties, elicits prompt, sustained, and clot-selective coronary thrombolysis.
引用
收藏
页码:1429 / 1436
页数:8
相关论文
共 22 条
[1]   TEMPORAL DEPENDENCE OF BENEFICIAL-EFFECTS OF CORONARY THROMBOLYSIS CHARACTERIZED BY POSITRON TOMOGRAPHY [J].
BERGMANN, SR ;
LERCH, RA ;
FOX, KAA ;
LUDBROOK, PA ;
WELCH, MJ ;
TERPOGOSSIAN, MM ;
SOBEL, BE .
AMERICAN JOURNAL OF MEDICINE, 1982, 73 (04) :573-581
[2]  
BERGMANN SR, 1983, SCIENCE, V220, P1181
[3]   THROMBOLYTIC THERAPY [J].
COLLEN, D ;
STUMP, DC ;
GOLD, HK .
ANNUAL REVIEW OF MEDICINE, 1988, 39 :405-423
[4]  
EISENBERG PR, 1987, THROMB HAEMOSTASIS, V57, P35
[5]   PREVENTION OF CORONARY-THROMBOSIS WITH SUBTHROMBOLYTIC DOSES OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR [J].
FOX, KAA ;
ROBISON, AK ;
KNABB, RM ;
ROSAMOND, TL ;
SOBEL, BE ;
BERGMANN, SR .
CIRCULATION, 1985, 72 (06) :1346-1354
[6]   CORONARY THROMBOLYSIS - PHARMACOLOGICAL CONSIDERATIONS WITH EMPHASIS ON TISSUE-TYPE PLASMINOGEN-ACTIVATOR (T-PA) [J].
FOX, KAA ;
BERGMANN, SR ;
SOBEL, BE .
BIOCHEMICAL PHARMACOLOGY, 1984, 33 (12) :1831-1838
[7]   CLEARANCE OF A NOVEL RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR IN RABBITS [J].
FU, KP ;
LEE, S ;
HETZEL, N ;
FENICHEL, R ;
HUM, HW ;
SPETH, J ;
KALYAN, N ;
HUNG, PP .
THROMBOSIS RESEARCH, 1988, 50 (05) :679-685
[8]   COMPARATIVE PROPERTIES OF 2 CLINICAL PREPARATIONS OF RECOMBINANT HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION [J].
GARABEDIAN, HD ;
GOLD, HK ;
LEINBACH, RC ;
JOHNS, JA ;
YASUDA, T ;
KANKE, M ;
COLLEN, D .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1987, 9 (03) :599-607
[9]   ACUTE CORONARY REOCCLUSION AFTER THROMBOLYSIS WITH RECOMBINANT HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR - PREVENTION BY A MAINTENANCE INFUSION [J].
GOLD, HK ;
LEINBACH, RC ;
GARABEDIAN, HD ;
YASUDA, T ;
JOHNS, JA ;
GROSSBARD, EB ;
PALACIOS, I ;
COLLEN, D .
CIRCULATION, 1986, 73 (02) :347-352
[10]  
LEE SG, 1988, J BIOL CHEM, V263, P2917